+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 18 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are investigating treatments for hormone receptor-positive and HER2-negative breast cancer that is either locally advanced and cannot be removed by surgery or has spread to other body parts. The study focuses on comparing patritumab deruxtecan with chemotherapy or trastuzumab deruxtecan to see if patients live longer or have delayed cancer progression. This phase 3 trial evaluates these treatments in people who have had prior progression on CDK46 inhibitor plus endocrine therapy. Participants receive either patritumab deruxtecan through intravenous infusion every three weeks for about 13 months or treatment chosen by their doctor, which may include various chemotherapy drugs or trastuzumab deruxtecan up to 13 months. Treatments are given in cycles with specific dosing schedules depending on the drug selected. Rescue medications are also allowed as needed following approved guidelines. During the study, participants undergo regular assessments including scans to measure disease progression and evaluations of quality of life using standardized questionnaires. Researchers monitor overall survival and progression-free survival for up to 85 months. Safety is closely followed by recording adverse events and treatment discontinuations. The trial aims to provide detailed data on how these treatments affect patients over time and their impact on symptoms and functioning.

Age: 18Years +All GendersPhase 3
206 locations
C

Actively Recruiting

Researchers are evaluating treatments for advanced HRD-positive high-grade ovarian cancer, fallopian tube cancer, primary peritoneal carcinoma, and clear cell carcinoma of the ovary in patients who have no residual tumor after primary tumor debulking. This phase II, multicenter, randomized, open-label study compares the recurrence-free survival of patients receiving either 3 cycles of carboplatin plus paclitaxel followed by maintenance therapy with niraparib or 6 cycles of the same chemotherapy plus niraparib maintenance. The study includes patients with specific disease stages FIGO IIIA to IV and uses genetic testing to stratify patients based on tumor characteristics.

Age: 18Years +FEMALEPhase 2
50 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
T

Actively Recruiting

Researchers are studying the use of Trastuzumab Deruxtecan T-DXd as an adjuvant treatment compared to standard chemotherapy, with or without radiotherapy, in women with newly diagnosed HER2-expressing endometrial cancer. This phase 3, open-label global trial aims to assess the safety and effectiveness of these treatments in participants who have not previously received anticancer therapy. The study focuses on participants with specific stages and various levels of HER2 expression in their cancer. Participants will be randomly assigned to receive either T-DXd at a dose of 5.4 mgkg intravenously every three weeks, with optional radiotherapy, or standard chemotherapy consisting of carboplatin and paclitaxel given every three weeks, with or without radiotherapy or chemoradiotherapy including cisplatin as a radiosensitizer. This comparison will evaluate how well these treatments work as adjuvant therapy following surgery. The study will continue until disease recurrence or other defined endpoints. During the study, participants will be monitored for disease-free survival using imaging reviewed by a blinded independent central review or local histopathologic confirmation, up to about 51 months after randomization. Overall survival will also be tracked up to approximately 63 months. Assessments will include radiographic evaluations and safety monitoring. Participants can expect regular visits for treatment and follow-up over several years to measure outcomes and ensure safety throughout the trial period.

Age: 18Years +FEMALEPhase 3
86 locations
N

Actively Recruiting

Researchers are evaluating how well asciminib works in patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase Ph CML-CP. The study includes adults who are either newly diagnosed or have previously been treated with one ATP-competitive tyrosine kinase inhibitor TKI. The goal is to understand asciminibs real-world tolerability, safety, and effectiveness compared to other TKIs. Patients are divided into three groups those treated with asciminib who may have had prior TKI treatment, and two groups of newly diagnosed patients treated with either imatinib or second-generation TKIs like dasatinib, bosutinib, or nilotinib. Treatment decisions are made by the patients doctor as part of routine care, and the study observes patients who begin treatment within 14 days before or after enrollment. Participants will be followed through routine visits and asked to complete questionnaires about their health and treatment experience. Researchers will measure molecular responses at various time points up to 24 months, including major molecular response at 12 months. They will also track medication adherence, quality of life, work productivity, and reasons for dose changes or treatment interruptions. The study collects detailed data to assess treatment outcomes and tolerability over time.

Age: 18Years - 100YearsAll Genders
69 locations
P

Actively Recruiting

This research aims to evaluate the effectiveness of AZD5335 compared to standard treatments in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. The study focuses on whether AZD5335 improves progression-free survival PFS among participants with either high or low levels of folate receptor alpha FR. Approximately 1100 adult women will be enrolled and divided into two groups based on their FR levels. Participants will be randomized within each group to receive either AZD5335 or the relevant standard treatment. Those with high FR levels will receive AZD5335 or mirvetuximab soravtansine, while those with low FR levels will receive AZD5335 or a chemotherapy agent chosen by the investigator, including paclitaxel, pegylated liposomal doxorubicin, or topotecan. Treatments are given intravenously, and participants will continue treatment until disease progression or other reasons for stopping. During the study, participants will undergo regular tumor assessments to monitor disease status. Researchers will follow all participants over time to evaluate overall survival. Safety and efficacy data will be reviewed periodically by an independent committee. The primary outcome is progression-free survival, measured for up to about five years. The study completion is expected by late 2029.

Age: 18Years +FEMALEPhase 3
299 locations
P

Actively Recruiting

Researchers are evaluating the effects of BAROSTIM THERAPY using the BAROSTIM NEO System in people with heart failure who have reduced ejection fraction. This registry study includes subjects recently implanted with the device under approved criteria for heart failure, specifically those with New York Heart Association NYHA functional Class III and left ventricular ejection fraction LVEF of 35% or less despite guideline-directed therapy. The study aims to understand how this therapy performs in a real-world commercial setting. Participants who received the BAROSTIM NEO System within 30 days before enrollment will be followed. Data will be collected from standard care measurements taken before implantation, at enrollment, and then at 3, 6, and 12 months after implantation. The study will track changes in heart failure severity, exercise capacity, heart function, biomarkers, device usage, and healthcare use such as hospitalizations related to heart failure. During the study, participants will undergo evaluations including assessments of their NYHA functional class, six-minute hall walk test, echocardiogram measurements, and blood tests for biomarkers like NT-pro BNP and Troponin HsT. Researchers will monitor hospitalizations over the 12-month follow-up. Each participant will complete the study after 12 months of monitoring following device implantation.

All AgesAll Genders
30 locations
E

Actively Recruiting

This research aims to evaluate the effects of BAROSTIM THERAPY using the BAROSTIM NEO System in people recently implanted with this device for resistant hypertension. The study observes patients implanted under the CE-Marked indication to assess how the therapy works in a commercial setting. The registry includes participants implanted within the past 30 days who meet specific blood pressure and medication resistance criteria. Participants in this registry have the BAROSTIM NEO System implanted and are followed over time without additional treatment interventions, as this is an observational study. Data are collected from standard medical care measurements taken before implantation, at enrollment, and at 3, 6, and 12 months after implantation. After the first year, data collection continues every six months for up to three years, providing long-term observation of therapy impact. During the study, participants undergo regular assessments of blood pressure, changes in cardiovascular medications, and health care use from before implant through three years post-implant. Researchers collect this information during routine care visits, and participants remain under usual medical supervision. The total participation duration can be up to three years from implantation, with data collected at scheduled intervals to monitor the therapys ongoing effects.

All AgesAll Genders
26 locations
P

Actively Recruiting

Researchers are collecting real-world data on the BioFreedom Ultra CoCr Biolimus A9 Coated Coronary Stent System in patients who have undergone percutaneous coronary intervention PCI. This prospective, observational registry study involves up to 10,000 patients treated at up to 150 cardiology centers across Europe, South America, the Middle East, and Asia over five years. The study provides post-market clinical follow-up as part of ongoing post-market surveillance. Participants receive the BioFreedom Ultra device, which consists of a cobalt chromium stent platform coated on the outside with the active ingredient BA9, without polymer or carrier. The study observes the use of this device in standard clinical practice without altering patient care. Patients are monitored mainly through telephone or clinic visits one year after PCI. During the study, participants will be followed for 12 months to collect data on outcomes such as target lesion failure, clinically driven target lesion revascularization, cardiovascular death, target vessel myocardial infarction, target vessel revascularization, and stent thrombosis. Follow-up assessments are conducted primarily by phone, ensuring safety monitoring and data collection in a real-world setting with minimal disruption to participants routine care.

Age: 18Years +All Genders
10 locations
R

Actively Recruiting

This trial investigates the diagnostic accuracy of gadopiclenol compared to gadoterate meglumine in adult patients suspected of having steno-occlusive disease affecting supra-aortic, peripheral, or abdominalrenal arteries. The study aims to evaluate these two contrast agents using magnetic resonance angiography MRA on commercial MRI scanners to improve the assessment of vascular diseases. It is a randomized, double-blind, crossover phase 3 trial sponsored by Guerbet. Participants receive two MRA procedures with each contrast agent given at a dose of 0.1 mmolkg. One group receives gadopiclenol first followed by gadoterate meglumine, while the other group receives the reverse order. The crossover design allows comparison within the same patient. The study evaluates the diagnostic performance and safety of each agent. During the trial, participants undergo MRI scans with MRA sequences using both contrast agents. Researchers monitor adverse events and assess diagnostic accuracy over 30 days following administration. Patients are evaluated for vascular disease symptoms and prior imaging results. The total participation includes imaging visits and follow-up assessments to ensure safety and collect outcome data.

Age: 18Years +All GendersPhase 3
43 locations

1-10 of 18

1